D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson's disease (PD), Alzheimer's disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical trials to treat NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03 that is in Phase I clinical trials for the treatment of PD, AD, and neuroinflammation; PMI04, which is in Phase I clinical trials to treat PD, AD, ALS, and depression; and PMI05 and PMI06 that are in Phase I clinical trials for the treatment of oncology and immuno-oncology. Its preclinical drug candidates include NLY03 for stroke/PD; DD03 to treat obesity and NASH; TLY014 for the treatment of tumor microenvironment; PMI31 for various cancers; and VT01 to treat PD. In addition, the company develops NLY02 for the treatment of PD & AD; NLY12 for type 2 diabetes and obesity; DD02 to treat type 2 diabetes; PMI21 for the treatment of prostate cancer; and PMI07 for oncology and fibrosis. Further, it focuses on the application of big data in CNS drug research and diagnostics. The company was founded in 2014 and is based in Seongnam-si, South Korea.